Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study

BACKGROUND: Trastuzumab emtansine (T-DM1) has demonstrated improvements in survival and neurological symptoms in patients with breast cancer with brain metastases (BCBM). This real-world study investigated the effectiveness of T-DM1 versus lapatinib plus capecitabine (LC) in patients with BCBM. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanglier, Thibaut, Shim, Jinjoo, Lamarre, Neil, Peña-Murillo, Claudia, Antao, Vincent, Montemurro, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300572/
https://www.ncbi.nlm.nih.gov/pubmed/36709091
http://dx.doi.org/10.1016/j.breast.2023.01.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300572/
https://www.ncbi.nlm.nih.gov/pubmed/36709091
http://dx.doi.org/10.1016/j.breast.2023.01.007

Ejemplares similares